23-Jan-2026
Polen Global Growth Portfolio adds to Taiwan Semiconductor, trims stake in Oracle in Q4 2025
Seeking Alpha News (Thu, 22-Jan 11:32 AM ET)
TipRanks (Thu, 22-Jan 10:10 AM ET)
TipRanks (Wed, 21-Jan 9:50 PM ET)
Merck added to BofA's best ideas list—see all the names
Seeking Alpha News (Wed, 21-Jan 5:33 PM ET)
Boston Scientific Advises Removal Of Certain AXIOS Stents After Deployment Issues Surface
Benzinga (Wed, 21-Jan 12:30 PM ET)
TipRanks (Tue, 20-Jan 6:50 PM ET)
Globe Newswire (Tue, 20-Jan 4:21 PM ET)
Boston Scientific Advances CHORUS IDx: New Imaging Study Targets Smarter Atrial Ablation
TipRanks (Tue, 20-Jan 11:30 AM ET)
PRNewswire (Fri, 16-Jan 2:06 PM ET)
Has BSX been a good buy before earnings?
Market Chameleon (Fri, 16-Jan 5:59 AM ET)
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for roughly 36% of the firm's total sales.
Boston Scientific trades on the NYSE stock market under the symbol BSX.
As of January 23, 2026, BSX stock price climbed to $92.51 with 12,391,742 million shares trading.
BSX has a beta of 0.96, meaning it tends to be less sensitive to market movements. BSX has a correlation of 0.41 to the broad based SPY ETF.
BSX has a market cap of $137.19 billion. This is considered a Large Cap stock.
Last quarter Boston Scientific reported $5 billion in Revenue and $.75 earnings per share. This beat revenue expectation by $93 million and exceeded earnings estimates by $.04.
In the last 3 years, BSX traded as high as $109.50 and as low as $45.44.
The top ETF exchange traded funds that BSX belongs to (by Net Assets): VTI, VOO, IVV, SPY, VUG.
BSX has underperformed the market in the last year with a price return of -9.0% while the SPY ETF gained +14.2%. BSX has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -9.6% and -5.3%, respectively, while the SPY returned +2.9% and -0.7%, respectively.
BSX support price is $89.75 and resistance is $92.83 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BSX shares will trade within this expected range on the day.